NEWTOWN, Pa., June 26, 2014 /PRNewswire/ -- BioClinica®, Inc., the world's leading provider of medical imaging and cardiovascular safety services for the pharmaceutical, biotechnology, and medical device industries, announced today that their neuroscience clinical trial experts will present recent clinical trial progress on the front against Alzheimer's Disease (AD) at this year's Alzheimer's Association International Conference (AAIC) in Copenhagen Denmark on July 12-17th. BioClinica's deep neuroscience expertise will be showcased in a series of key presentations which include 6 scientific posters and an oral presentation, as well as an invitation to chair a session on neuroimaging.
Several of BioClinica's neuroscience experts, including Joyce Suhy, PhD, Gregory Klein, PhD, and Chahin Pachai, PhD, will be on hand at the conference to discuss important scientific work related to brain imaging for advancing Alzheimer's disease (AD) clinical trials. "Advances in brain imaging including PET and functional MRI are proving instrumental for accurate patient selection and evaluation of new treatments in clinical trials for AD," said Joyce Suhy, VP of Neuroscience at BioClinica. "We are excited for the opportunity to partner with and support pharmaceutical companies and researchers who are developing next generation treatments for AD." Dr. Suhy will also chair a session focused on neuroimaging in clinical trials which will highlight recent advances in the area of molecular imaging that provide clinicians with sophisticated tools for monitoring AD. This session will include a presentation co-authored by BioClinica team members, on the subject of recent trial progress using amyloid PET screening for early stage AD patient recruitment.
BioClinica is the world's foremost medical imaging core lab for neuroscience clinical trials. The company's extensive resources include a dedicated team of neuroradiologists, image processing scientists and molecular and functional imaging experts making BioClinica the leading authority in clinical trial services for Alzheimer's clinical trials. "The team at BioClinica continues to be at the forefront in the use advanced imaging modalities in Alzheimer's clinical trials, as is demonstrated by a diverse and extensive set of presentations at this year's conference," stated Michael Weiner, MD, Scientific Advisor at BioClinica.
BioClinica has supported the clinical development of numerous clinical trials in AD and related dementias with a broad range of expertise in advanced imaging assessments including structural and functional MRI and molecular tracers. For a complete list of BioClinica attendees at AAIC or to schedule a meeting with one of BioClinica's neuroscience experts, please visit BioClinica's website at www.bioclinica.com or contact Joyce Suhy at email@example.com.
BioClinica and SYNARC have merged to create the world's foremost medical imaging and cardiovascular core lab with unrivalled scientific, regulatory and project management capabilities for advancing clinical trials. Together, we offer the industry's most comprehensive and diversified clinical imaging program with therapeutically aligned experts, proven technologies and increased operational scale. With more than 30 years of experience supporting thousands of successful trials, BioClinica delivers for pharmaceutical, biotechnology, and device companies in their drug development efforts across a broad range of therapeutic areas. For more information, visit www.bioclinica.com
The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. As a part of the Association's research program, AAIC serves as a catalyst for generating new knowledge about Alzheimer's and fostering a vital and collegial research community.
SOURCE BioClinica, Inc.